stockrow
Monday 9 November 2026
Export PEPG’s income statement to Excel — free account
PepGen, Inc.
PEPG- EPS
- +62.9%
- Free cash flow
- +33.0%
Quarter to June 2026, against a year earlier
2.47
0.15
+6.47%
Follow PEPG
Alert me
PepGen, Inc. (PEPG) P/E ratio
PepGen, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WHWK Whitehawk Therapeutics, Inc. compare | n/m |
| MDWD MediWound Ltd. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| IPHA Innate Pharma S.A. Sponsored ADR compare | n/m |
| PEPG PepGen, Inc. | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | n/m |
| ORMP Oramed Pharmaceuticals Inc. compare | 0.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)